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OBJECTIVES: Atypical antipsychotics (AA) (e.g., olan-
zapine, risperidone) in combination with mood stabiliz-
ers (MS) (e.g., lithium, valproate) have demonstrated
better treatment response in acute bipolar mania com-
pared with MS monotherapy, and may be better tolerated
than conventional antipsychotics (e.g., haloperidol).
However, their acquisition costs are relatively high. The
objective of this study was to assess the cost-effectiveness
of AA in combination with MS in acute bipolar mania.
METHODS: We developed a state-transition Markov
model to estimate the cost-effectiveness of combination
therapy with AA + MS in acute bipolar mania. The incep-
tion cohort consists of patients hospitalized with a new
episode of acute mania. Each patient may receive: olan-
zapine + MS, risperidone + MS, haloperidol + MS, lithium
monotherapy, or valproate monotherapy as initial
therapy. Over subsequent 3-week cycles, patients initiated
on each therapy may remain manic, become depressed,
die from suicide or other causes, or stabilize and enter the
continuation/maintenance phase of treatment. While in
each health state, patients accumulate medical-care costs
(for drugs, hospitalization, etc.) and utility associated
with that state. The model tracks patients’ state transi-
tions over 24 weeks and tabulates cumulative costs and
utilities over the patients’ lifetime (discounted at an
annual rate of 3%) to estimate incremental cost per
quality-adjusted life-year (QALY) gained. Transition
probabilities between states were estimated from pub-
lished literature; costs were derived from standard
sources; utilities were assessed using the standard gamble
method. RESULTS: Haloperidol + MS is the least costly
therapy option, while risperidone + MS is the most effec-
tive. Risperidone + MS costs an additional $3300, and
olanzapine + MS an additional $8700, per QALY gained
versus haloperidol + MS. Both AA + MS combinations
were cost saving versus monotherapy with lithium or val-
proate. Results were sensitive to drug costs, drug efﬁcacy,
suicide rate, and rate of tardive dyskinesia. CONCLU-
SIONS: Based on current evidence, combination therapy
with AA + MS is cost-effective versus haloperidol + MS
in the treatment of acute mania, and dominates MS
monotherapy.
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OBJECTIVE: To measure effects on mental and other
healthcare expenses of family members of patients with
bipolar disorder, schizophrenia, and major depression.
METHODS: Using data from a 2-million member health
plan, the authors estimated and compared expenses for
mental and other healthcare services per person per
month (PPM) of family members of patients with bipolar
disorder, schizophrenia, and major depressive disorder
with those of controls. Ordinary least squares and logis-
tic regression models were used to estimate differences
and identify characteristics affecting healthcare expenses
within each group. RESULTS: Living with patients with
bipolar disorder, schizophrenia, or major depression
increased both mental and other healthcare expenses 
for family members, compared with controls. Mental and
other healthcare expenses increased as follows: bipolar
disorder, $8.85/PPM (213%; P < 0.0001) and $10.65/
PPM (7.4%; P < 0.0001); schizophrenia, $4.03/PPM
(81%; P < 0.0001) and $5.96/PPM (4.2%; P < 0.005);
major depression, $8.24/PPM (219%; P < 0.0001) and
$9.46 (6.5%; P < 0.0001). Within all three groups, men
were less likely to use mental healthcare services (P <
0.002), and the likelihood of mental healthcare use
increased with illness duration (P < 0.005). Within the
bipolar and major depression groups, parents and
spouses of patients were more likely to use mental health-
care services than children and siblings (P < 0.0001), and
the likelihood of mental healthcare use increased with
illness severity (P < 0.0001). Within all three groups,
other healthcare expenses were higher for parents and
spouses of patients (P < 0.0001–P < 0.01) and with longer
illness duration (P < 0.0001–P < 0.0005); men had lower
expenses (P < 0.0001–P < 0.05). Within the bipolar 
and major depression groups, other healthcare expenses
were higher for family members of older patients (P <
0.0001–P < 0.003). CONCLUSION: Living with a
person with serious mental illness signiﬁcantly increases
healthcare expenses of family members, especially for
mental healthcare. Family members of patients with
bipolar and major depressive disorders have higher
healthcare expenses than those of patients with schizo-
phrenia among commercially insured persons.
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